We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 49.01 | 49.00 | 49.79 | 0 | 01:00:00 |
From May 2019 to May 2024
By Inti Landauro
PARIS-- French pharmaceutical group Sanofi SA (SAN.FR) said it plans to file for registration of its dengue vaccine in 2015 in several countries where the disease is endemic after the publication of results of the final clinical study in Latin America.
The company said the vaccine's overall efficacy against any symptomatic dengue disease was 60.8% in children and adolescents, while analyses showed a 95.5% protection against severe dengue and an 80.3% reduction in the risk of hospitalization during the study.
Sanofi said the world's first dengue vaccine could be available in the second half of 2015.
Dengue is a disease transmitted by mosquitoes that is endemic in parts of Asia and Latin America and is expanding geographically. About 550,000 people are hospitalized every year due to severe dengue. The disease can develop in a hemorrhagic fever that can be deadly. Sanofi says dengue is a threat for 2.5 billion people.
-Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
